DUBLIN, Calif., Nov. 17 /PRNewswire/ -- Carl Zeiss Meditec, Inc., a leader in ophthalmic devices and systems, today announced the VISUCAM PRO NM non-mydriatic fundus camera for retinal imaging was granted 510(k) clearance by the U.S. Food and Drug Administration.
Building on Zeiss’ reputation for quality optics and innovation, VISUCAM PRO NM enables practitioners to capture high-resolution, digital images of the retina and posterior segment of the eye through the smallest pupil size in the industry (3.3 millimeters compared to the competitors’ 3.7 millimeters). This eliminates the need to dilate the pupil prior to testing.
Additionally, the technology captures high-resolution images at 30- and 45- degree field angles allowing for early documentation of such conditions as diabetic retinopathy, age-related macular degeneration (AMD) and glaucoma.
“Zeiss’ goal is to provide products that benefit clinicians and patients by improving outcomes, reducing costs and improving the quality of care throughout the ophthalmology industry,” said Jim Taylor, president and chief executive officer of Carl Zeiss Meditec, Inc. “The VISUCAM PRO NM accomplishes this goal by providing the most advanced fundus imaging available in the industry to document retinal pathology.”
Unlike other non-mydriatic fundus cameras on the market, VISUCAM PRO NM is an all-in-one unit without the need for external wires or peripheral cameras. The unit includes a 17-inch flat panel monitor, which can be easily rotated for patient education. The industrial-grade internal digital sensor requires no maintenance, keeping the optical path free of dust or other artifacts.
The VISUCAM PRO NM is based on Microsoft Windows XP(R) and is fully networkable, increasing practitioner workflow and efficiency, while allowing for easy export in a variety of formats.
For additional information about VISUCAM PRO NM or other products, contact Carl Zeiss Meditec Customer Service at (800) 342-9821.
About Carl Zeiss Meditec
Built on an unparalleled 150-year heritage of optical innovation, Carl Zeiss Meditec (International Securities Identification Number DE000531370) is one of the world’s leading eye care solutions providers. Its product line includes systems for the diagnosis and treatment of the four main diseases of the eye: refraction, cataract, glaucoma and retinal disorders.
The company has incorporated its technologically superior optics into a stream of product innovations throughout the years, from slit lamps and fundus cameras; to the Humphrey(R) Field Analyzer, recognized as the global standard for glaucoma detection and management; to its newest applications of lasers and light as embodied in its leading-edge MEL80(TM) refractive laser and eye-scanning Stratus OCT(TM) optical coherence tomographer.
Carl Zeiss Meditec AG is based in Jena, Germany, with key subsidiaries in the U.S. (Carl Zeiss Meditec Inc.) and Japan (Carl Zeiss Meditec Limited). The rapidly aging global population and other trends are expected to grow the ophthalmic market through 2010, and the company is focused on applying innovative optical technologies to protect and enhance vision now and into the future.
MEDIA CONTACT: Rebecca Macdonald, FischerHealth (310) 577-7870 ext. 116 rmacdonald@fischerhealth.com
Carl Zeiss Meditec, Inc.
CONTACT: Rebecca Macdonald of FischerHealth, +1-310-577-7870 ext. 116,rmacdonald@fischerhealth.com, for Carl Zeiss Meditec, Inc.
